Cleveland BioLabs Completes Recruitment for Prostate Cancer Trial
Cleveland BioLabs has enrolled all the patients in its Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory prostate cancer.
Thirty-two patients from four medical centers in the U.S. will be evaluated prior to treatment with the drug, as well as at one-month intervals for a maximum of six months.
The trial’s goals are to confirm safety and tolerability of the drug in patients with hormone-refractory metastatic prostate cancer and to evaluate the efficacy of the drug by assessing prostate-specific antigen levels, reductions in tumor size and disease-free survival periods.
The company said it expects results to be available in the fourth quarter of this year.
Source : fdanews.co
